Who Prioritizes Innovation? R&D Spending Compared for TG Therapeutics, Inc. and Viking Therapeutics, Inc.

Biotech R&D: TG Therapeutics vs. Viking Therapeutics

__timestampTG Therapeutics, Inc.Viking Therapeutics, Inc.
Wednesday, January 1, 20143135478122223073
Thursday, January 1, 2015434458176966842
Friday, January 1, 2016664898209000499
Sunday, January 1, 20179688613413741186
Monday, January 1, 201815379300019040000
Tuesday, January 1, 201914836900023559000
Wednesday, January 1, 202015193400031931000
Friday, January 1, 202119853200044981000
Saturday, January 1, 202211212800054234000
Sunday, January 1, 20237619200063806000
Loading chart...

Unleashing the power of data

Innovation in Biotech: A Tale of Two Companies

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, TG Therapeutics, Inc. and Viking Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, TG Therapeutics consistently outspent Viking Therapeutics, with an average R&D expenditure nearly four times higher. Notably, in 2021, TG Therapeutics peaked with a 198% increase in spending compared to 2014, while Viking Therapeutics showed a steady growth, culminating in a 187% increase over the same period. This disparity highlights TG Therapeutics' aggressive pursuit of innovation, while Viking Therapeutics adopts a more measured approach. As the biotech landscape evolves, these spending patterns may influence their competitive positioning and market success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025